Atossa Therapeutics
ATOS
$1.53
Share price
0.66%
Change (1 day)
142.86%
Change (1 year)
Categories
P/S ratio for Atossa Therapeutics (ATOS)
P/S ratio as of April 2024 (TTM): N/A
According to Atossa Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2023 the company had a P/S ratio of N/A.
P/S ratio history for Atossa Therapeutics from 2012 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | N/A | |
| 2022 | N/A | |
| 2021 | N/A | |
| 2020 | N/A | |
| 2019 | N/A | |
| 2018 | N/A | |
| 2017 | N/A | |
| 2016 | N/A | |
| 2015 | N/A | -100% |
| 2014 | 66.8 | -1.96% |
| 2013 | 68.1 | -34.85% |
| 2012 | 105 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.79 | N/A | 🇺🇸 USA |
 Quest Diagnostics
DGX | 1.61 | N/A | 🇺🇸 USA |
 LabCorp LH | 1.30 | N/A | 🇺🇸 USA |
 Translate Bio
TBIO.defunct | N/A | N/A | 🇺🇸 USA |
 NeoGenomics
NEO | 3.06 | N/A | 🇺🇸 USA |
 Enzo Biochem ENZ | 4.22 | N/A | 🇺🇸 USA |